- Home
- FBRX vs LXEO Comparison
FBRX vs LXEO Comparison
Compare FBRX & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBRX | LXEO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 369.8M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FBRX | LXEO |
|---|---|---|
| Price | $19.12 | $5.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $67.00 | $18.44 |
| AVG Volume (30 Days) | 178.8K | ★ 667.0K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | $36,000.00 | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.78 | $2.72 |
| 52 Week High | $35.80 | $10.99 |
Technical Indicators
Market Signals| Indicator | FBRX | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 32.53 | 43.41 |
| Support Level | $18.18 | $4.95 |
| Resistance Level | $34.44 | $6.26 |
| Average True Range (ATR) | 2.09 | 0.38 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 5.88 | 36.34 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.